Background: The novel Coronavirus SARS-CoV-2, which was identi fied after a recent outbreak in Wuhan, China, in December 2019, has generated a global pandemic impacting over 200 countries around the world. Recent reports suggest that ACE2, which is the target protein to invade the host, has a ubiquitous presence in human organs, including lung parenchyma, gastrointestinal tract, nasal mucosa, renal and urinary tract, airway epi- thelia, lymphoid tissues, reproductive organs, vascular endothelium and neurons. In this scenario, neurologists are particularly involved into considering even more speci fic therapeutic strategies according to the available data during the pandemic. In particular, MS patients are usually receiving disease -modifying therapies (DMTs) with immunosuppressant or immunomodulatory e ffects, which increase the risk of infections and morbidity, compared with the general population. Development of PML or other serious opportunistic infections during treatment with natalizumab forces to consider whether de -risking strategies are needed in this particular context and how to manage a high -e fficacy treatment. Methods: In this paper we report on a patient treated with natalizumab for relapsing MS who developed COVID- 19 and recovered in a few days without complications. Results: After recovery natalizumab has been administered in the window of the extended interval dosing (EID), without reporting any worsening or new symptoms. Discussion: This case supports the opportunity to avoid discontinuing or delaying the retreatment over 8 weeks in patients recovered from a recent COVID-19.

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach / Borriello, Giovanna; Ianniello, Antonio. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 41:(2020), p. 102165. [10.1016/j.msard.2020.102165]

COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach

Borriello, Giovanna
Primo
;
Ianniello, Antonio
Secondo
2020

Abstract

Background: The novel Coronavirus SARS-CoV-2, which was identi fied after a recent outbreak in Wuhan, China, in December 2019, has generated a global pandemic impacting over 200 countries around the world. Recent reports suggest that ACE2, which is the target protein to invade the host, has a ubiquitous presence in human organs, including lung parenchyma, gastrointestinal tract, nasal mucosa, renal and urinary tract, airway epi- thelia, lymphoid tissues, reproductive organs, vascular endothelium and neurons. In this scenario, neurologists are particularly involved into considering even more speci fic therapeutic strategies according to the available data during the pandemic. In particular, MS patients are usually receiving disease -modifying therapies (DMTs) with immunosuppressant or immunomodulatory e ffects, which increase the risk of infections and morbidity, compared with the general population. Development of PML or other serious opportunistic infections during treatment with natalizumab forces to consider whether de -risking strategies are needed in this particular context and how to manage a high -e fficacy treatment. Methods: In this paper we report on a patient treated with natalizumab for relapsing MS who developed COVID- 19 and recovered in a few days without complications. Results: After recovery natalizumab has been administered in the window of the extended interval dosing (EID), without reporting any worsening or new symptoms. Discussion: This case supports the opportunity to avoid discontinuing or delaying the retreatment over 8 weeks in patients recovered from a recent COVID-19.
2020
coronavirus; covid 19; extended interval dosing; multiple sclerosis; natalizumab; relapsing remitting multiple sclerosis
01 Pubblicazione su rivista::01i Case report
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach / Borriello, Giovanna; Ianniello, Antonio. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 41:(2020), p. 102165. [10.1016/j.msard.2020.102165]
File allegati a questo prodotto
File Dimensione Formato  
Borriello_Covid19_2020.pdf

accesso aperto

Note: Borriello_Covid19_2020
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 145.32 kB
Formato Adobe PDF
145.32 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1669810
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact